Arbutus Biopharma Corporation

NasdaqGS:ABUS

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

💉 Vaccines

Location

United States

Market Cap

USD 653.11 M

Share Price

USD 3.41

Avg Daily Volume

972,490

Change (1 day)

-0.58%

Change (1 year)

11.80%

Change (YTD)

4.28%

Arbutus Biopharma Corporation Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2025: USD -26.10 M

Arbutus Biopharma Corporation Common Stock Issued is USD -26.10 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -182.18% change year over year. Common stock issued is cash received from issuing new shares of the company’s common stock.

Arbutus Biopharma Corporation Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 31.75 M, a -20.58% change year over year.
Arbutus Biopharma Corporation Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 39.98 M, a -63.15% change year over year.
Arbutus Biopharma Corporation Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 108.51 M, a 8.08% change year over year.
Arbutus Biopharma Corporation Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 100.40 M, a 250.22% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

NasdaqGS: ABUS

Arbutus Biopharma Corporation

CEO	Ms. Lindsay Androski J.D., M.B.A.
IPO Date	July 26, 2007
Location	United States
Headquarters	701 Veterans Circle
Employees	44
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals 💉 Vaccines

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.